Trial Profile
A study of RVT-801 for Farber disease
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs ACG 801 (Primary)
- Indications Farber lipogranulomatosis
- Focus Adverse reactions; First in man; Registrational
- Acronyms ADVANCE
- Sponsors Enzyvant; Sumitomo Pharma America
- 17 Jan 2023 According to an Aceragen media release, Idera Pharmaceuticals has changed its name to Aceragen
- 17 Jan 2023 According to an Aceragen media release, company anticipate to initiate this study in the first quarter of 2024 with data expected in the first quarter of 2025.
- 28 Sep 2022 According to an Aceragen media release, the Company expects to initiate the ADVANCE clinical study for ACG-801 in Farber disease in Q1 2023 with data expected in Q1 2024